Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy

These findings reveal differences in T-cell activation between responders and nonresponders early into anti-PD-1 treatment, which may impact many facets of immuno-oncology, including patient selection, management, and development of novel combinatorial approaches.